EVerZom enters research and licensing agreement with GENFIT
Charlie Blackie-Kelly | November 13, 2025 | News story | Research and Development | EVerZom, Eviv, GENFIT, Liver Diseases, collaboration, licensing agreement
EVerZom, a French biotech company developing exosome-based therapies for regenerative medicine, has entered into a research and licensing agreement with GENFIT, a biopharma company specialising in rare liver diseases.
The collaboration will focus on evaluating EViv, an intravenous exosome formulation designed to counter inflammatory storms through multiple mechanisms of action.
The programme will assess its potential efficacy in treating Acute-on-Chronic Liver Failure (ACLF) – a severe hepatic syndrome characterised by systemic inflammation, multiple organ failure and high short-term mortality. Current therapeutic options remain limited, with liver transplantation representing the only definitive treatment.
“This first research partnership for EViv marks an important milestone in EVerZom’s strategy: demonstrating the clinical versatility of exosomes in regenerative medicine across indications with significant unmet need, such as hepatology, dermatology, and ophthalmology. GENFIT is an ideal partner to accelerate proof-of-concept and prepare clinical access in Acute-on-Chronic Liver Failure (ACLF),” said Jeanne Volatron, Co-Founder and CEO of EVerZom.
Under the terms of the agreement, EVerZom will contribute its proprietary expertise in exosome engineering and bioproduction. GENFIT will lead the preclinical evaluation of EViv, with the option to exercise an exclusive licence for acute liver disease treatments pending positive in vivo proof-of-concept results. The agreement also grants GENFIT authority to make a go/no-go decision on clinical progression after 18 months.
“This collaboration demonstrates the ability of EVerZom to transform its scientific excellence into industrial momentum and work with leading partners. It also strengthens the company’s positioning in the regenerative therapies market,” added Michel Finance, Chairman of EVerZom’s Board of Directors.
Related Content
Custom Pharmaceuticals launches new company for drug product development
Customs Pharmaceuticals, a full-service contract development and manufacturing organisation (CDMO), has launched Centrix Pharma Solutions, …
EVerZom receives €3m funding from French government to industrialise exosome technology
EVerZom, a French biopharma company focused on exosome-based therapies, has announced it has received €3m …
AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …
